Glomerulonephritis, Membranous clinical trials at UCSF

• Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

  open to eligible people ages 18-80

  This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

  San Francisco, California and other locations

Last updated: February 12, 2021